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The liver plays a central role in hemostasis by synthesizing clotting factors, coagulation inhibitors, and ﬁbrinolytic proteins. Liver
cirrhosis (LC), therefore, impacts on both primary and secondary hemostatic mechanisms. ADAMTS13 is a metalloproteinase,
producedexclusivelyinhepaticstellatecells,andspeciﬁcallycleavesunusuallylargevonWillebrandfactormultimers(UL-VWFM).
Deﬁciency of ADAMTS13 results in accumulation of UL-VWFM, which induces platelet clumping or thrombi under high shear
stress, followed by sinusoidal microcirculatory disturbances and subsequent progression of liver injuries, eventually leading to
multiorganfailure.ThemarkedimbalancebetweendecreasedADAMTS13activity(ADAMTS13:AC)andincreasedproductionof
UL-VWFM indicating a high-risk state of platelet microthrombi formation was closely related to functional liver capacity, hepatic
encephalopathy, hepatorenal syndrome, and intractable ascites in advanced LC. Some end-stage LC patients with extremely low
ADAMTS13:AC and its IgG inhibitor may reﬂect conditions similar to thrombotic thrombocytopenic purpura (TTP) or may
reﬂect “subclinical TTP.” Hence, cirrhotic patients with severe to moderate deﬁciency of ADAMTS13:AC may be candidates for
FFP infusion as a source of ADAMTS13 or for recombinant ADAMTS13 supplementation. Such treatments may improve the
survival of patients with decompensated LC.
1.Introduction
The liver is a major source of clotting and ﬁbrinolytic pro-
teins and plays a central role in thromboregulation [1–4].
Liver diseases, hence, impact on both primary and secondary
hemostatic mechanisms. Because the hemostatic system
is normally in a delicate balance between pro-hemostatic
and antihemostatic processes, advanced liver cirrhosis (LC)
patients experience multiple changes in the hemostatic
system that may lead to either bleeding or thrombosis [1–
4]. Despite clinical evidence of increasing bleeding tendency
in LC patients, many facts indicate local and systemic
hypercoagulability including portal or hepatic vein throm-
bosis, pulmonary embolism, and deep vein thrombosis,
which are closely related to microcirculatory disturbances
[4]. Deﬁciency of anticoagulant proteins and high levels of
several procoagulant factors may favor hypercoagulability
[4], but the mechanisms underlying this disorder have not
been fully elucidated.
ADAMTS13 (ad isintegrin-like and metalloproteinase
with thrombospondin type-1 motifs 13) is a metallopro-
teinase that speciﬁcally cleaves multimeric von Willebrand
factor (VWF) between Tyr1605 and Met1606 residues in the
A2 domain [5, 6]. In the absence of ADAMTS13 activity
(ADAMTS13:AC), unusually large VWF multimers (UL-
VWFMs) are released from vascular endothelial cells (ECs)
and improperly cleaved, causing them to accumulate and to
induce the formation of platelet thrombi in the microvas-
culature under conditions of high shear stress. Currently, a
severe deﬁciency in ADAMTS13:AC, which results either2 International Journal of Hepatology
from genetic mutations in the ADAMTS13 gene (Upshaw-
Schulman syndrome, (USS)) [5–8] or acquired autoantibod-
ies against ADAMTS13 [9, 10], is thought to be a speciﬁc
feature of thrombotic thrombocytopenic purpura (TTP)
[5–12].
In 2000, we demonstrated that a decreased plasma
ADAMTS13:AC in patients with cirrhotic biliary atresia can
be fully restored after liver transplantation, indicating that
the liver is the main organ producing ADAMTS13 [13].
One year later, northern blot analysis showed that the 4.6-
kilobaseADAMTS13mRNAwashighlyexpressedintheliver
[7, 14, 15], and subsequently both in situ hybridization and
immunohistochemistry clearly indicated that ADAMTS13 is
produced exclusively in hepatic stellate cells (HSCs) [16].
Platelets [17], vascular ECs [18], and kidney podocytes [19]
have also been implicated as ADAMTS13-producing cells,
but the amount produced by these cell types in the liver
appears to be far less than that produced by HSC.
Mannucci et al. [20] originally reported a reduction of
the ADAMTS13:AC in advanced LC. Since HSCs were
showntobethemajorproducingcellsintheliver[16],much
attention has been paid to the potential role of ADAMTS13
in the pathophysiology of liver diseases associated with sinu-
soidal and/or systemic microcirculatory disturbance [21–
35]. ADAMTS13:AC signiﬁcantly decreased in patients with
hepatic veno-occlusive disease (VOD) [22, 23], alcoholic
hepatitis [24–27], liver cirrhosis [29, 30], and those un-
dergoing living-donor-related liver transplantation [31–33]
and partial hepatectomy [34]. Furthermore, hepatitis C
virus-(HCV-)relatedLCpatientswithADAMTS13inhibitor
(ADAMTS13:INH) typically developed TTP [35]. Once
patients with LC develop a decompensated condition, the
risk of early mortality sharply increases for speciﬁc life-
threatening complications such as ascites, hepatic enceph-
alopathy,sepsis,hepatorenalsyndrome,orhepatopulmonary
syndrome [36].
In this paper, we will focus on the importance of
ADAMTS13 determination for a better understanding of
pathophysiology and/or for possible therapeutic approaches
of ADAMTS13 supplementation to improve survival in
patients with advanced LC.
2. HepaticMicrocirculationand
HypercoagulableStateinLC
Hepatic microcirculation compromises a unique system of
capillaries,calledsinusoids,whicharelinedbythreediﬀerent
cell types: sinusoidal endothelial cells (SECs), HSC, and
Kupﬀer cells [37] .T h eS E Cm o d u l a t e sm i c r o c i r c u l a t i o n
between hepatocytes and the sinusoidal space through the
sinusoidalendothelialfenestration.TheSEChastremendous
endocytic capacity, including VWF and the extracellular
matrix, and secretes many vasoactive substances [37]. The
HSC is located in the space of Disse adjacent to the SEC and
regulates sinusoidal blood ﬂow by contraction or relaxation
induced by vasoactive substances [38]. Kupﬀer cells are
intrasinusoidally located tissue macrophages and secrete
potent inﬂammatory mediators during the early phase of
liver inﬂammation [37]. Intimate cell-to-cell interaction has
been found between these sinusoidal cells and hepatocytes
[37, 38]. In LC, a sinusoidal microcirculatory disturbance
occurs when the normal hepatic structure is disrupted
by ﬁbrin deposition [39] or by impaired balance between
the action of vasoconstrictors and vasodilators in hepatic
vascular circulation [37]. Studies have shown that cirrhotic
liver exhibits a hyperresponse to vasoconstrictors, including
catecholamine, endothelin, and leukotrienes D4 [37].
Vascularendothelialcellsplayapivotalroleinhemostasis
and thrombosis [5, 6]. VWF is a marker of endothelial cell
activation (damage) and plays an essential role in hemostasis
[5, 6]. In the normal state, VWF immunostaining is usually
positive in large vessels but negative in the SEC [40]. On the
occurrence of liver injury accompanied by a necroinﬂamma-
tory process, the SEC becomes positive for VWF, presumably
in association with the capillarization of hepatic sinusoids
[39]. Subsequently, platelets adhere to subendothelial tissue
mediatedbyUL-VWFM[5,6].ADAMTS13thencleavesUL-
VWFM into smaller VWF multimers [5, 6]. This interaction
of ADAMTS13 and UL-VWFM is, indeed, the initial step in
hemostasis [5, 6].
In patients with LC, circulating plasma VWF levels are
extremely high [41, 42]. In liver tissue from cirrhotics [43]
and even from the early stages of alcoholic liver diseases [44],
VWF immunostaining shows positive cells predominantly
at the scar-parenchyma interface, within the septum, and
in the sinusoidal lining cells. Actually, portal or hepatic
vein thrombosis is often observed in advanced LC routinely
screened with Doppler ultrasound [45], and, in cirrhotic
liver removed at transplantation, intimal ﬁbrosis suggesting
hepatic and portal vein thrombosis was frequently observed
[46]. An autopsy series revealed microthrombi in one or
multiple organs in one-half of cirrhotics [47]. Such a hy-
percoagulable state in liver diseases may be involved in
hepatic parenchymal destruction, the acceleration of liver
ﬁbrosis and disease progression [4], leading to hepatorenal
syndrome, portopulmonary hypertension, and spontaneous
bacterial peritonitis [48].
Systemically, deﬁciency of anticoagulant proteins (anti-
thrombin, protein C, and protein S) and the high levels of
severalprocoagulantfactors(factorVIIIandVWF)maycon-
tribute to hypercoagulability in patients with LC [4]. Locally,
the SEC dysfunction could lead to the development of a
hypercoagulable state at the hepatic sinusoids corresponding
to the site of liver injury, even in the face of a systemic
hypocoagulable state [4]. Considering that ADAMTS13
is synthesized in HSC and its substrate, UL-VWFM, is
produced in transformed SEC during liver injury, decreased
plasma ADAMTS13:AC may involve not only sinusoidal
microcirculatory disturbances, but also subsequent progres-
sion of liver diseases, ﬁnally leading to multiorgan failure.
Based on these ﬁndings, it is of particular interest to evaluate
the activity of plasma ADAMTS13:AC in LC patients.
3. Cleavage of UL-VWFM by ADAMTS13
Although the mechanism by which TTP develops in the
absence of ADAMTS13:AC has not been fully elucidated,International Journal of Hepatology 3
accumulating evidence has provided a hypothesis as illus-
trated in Figure 1 [49]. UL-VWFMs are produced exclusively
in vascular ECs and stored in an intracellular organelle
termed Weidel-palade bodies (WPBs) and then released
into the circulation upon stimulation. Under physiological
conditions, epinephrine acts as an endogenous stimulus, but
under nonphysiological conditions, DDAVP (1-deamino-
8-D-arginine vasopressin), hypoxia, and several cytokines
such as interleukin IL-2, IL-6, IL-8, and tumor necrosis
factor- (TNF-) α act as stimuli that upregulate VWF
release. Once ECs are stimulated, UL-VWFMs and P-
selectin, both stored in WPBs, move to the membrane
surface of ECs, where P-selectin anchors UL-VWFMs on
the ECs surface [50]. Under these circumstances, high shear
stress generated in the microvasculature induces a change
in the UL-VWFM from a globular to an extended form
[51] .T h eA D A M T S 1 3p r o t e a s ee ﬃciently cleaves the active
extended form of UL-VWFM between the Tyr1605 and
Met1606 residues in the A2 domain [52]. In this context,
it has been postulated that multiple exocites within the
disintegrin-like/TSP1/cysteine-rich/spacer (DTCS) domains
of ADAMTS13 play an important role in interacting with
the unfolded VWF-A2 domain [53]. ADAMTS13 may more
eﬃciently cleave newly released UL-VWFMs that exist as
solid-phase enzymes anchored to the vascular EC surface
by binding to CD36, because CD36 is a receptor for TSP1,
which is a repeated domain within the ADAMTS13 molecule
[54]. When ADAMTS13 activity is reduced, UL-VWFM
interacts more intensively with platelet GPIb and generates
signals that further accelerate platelet activation [5, 6]. A
series of these reactions leads to platelet microaggregates
and thrombocytopenia. However, little information has been
available on the cleavage of the UL-VWFMs by ADAMTS13
in the sinusoidal microcirculation in LC.
4. Assaysfor Plasma ADAMTS13:AC and
ADAMTS13:INH
ADAMTS13:AC was determined with a classic VWFM assay
in the presence of 1.5mol/L urea using puriﬁed plasma-
derived VWF as a substrate according to the method
described by Furlan et al. [55], and the detection limit of this
assay was 3% of the normal control in our laboratory [56].
In2005,wedevelopedanovelchromogenicADAMTS13-act-
ELISA using both an N- and C-terminal tagged recombinant
VWF substrate (termed GST-VWF73-His). This assay was
highly sensitive, and the detection limit was 0.5% of the
normal control [57]. Plasma ADAMTS13:AC levels highly
correlatedbetweenVWFMassayandADAMTS13-act-ELISA
(mean±SD, 102 ± 23% versus 99.1 ± 21.5%, r2 = 0.72,
P<. 01) [57]. No interference of the ADAMTS13-act-ELISA
occurred even in the presence of hemoglobin, bilirubin,
or chylomicrons in the samples, thus enabling distinction
from the FRETS-VWF73 assay [58]. Because of its high
sensitivity, easy handling, and lack of interference from
plasma components, the ADAMTS13-act-ELISA would be
recommended for routine laboratory use.
The ADAMTS13:INH has also been evaluated with the
chromogenic act-ELISA by means of the Bethesda method
[59]. Prior to the assay, the test samples were heat-treated
at 56◦C for 60min to eliminate endogenous enzyme activity,
mixed with an equalvolume of intact normal pooled plasma,
and incubated for 2 hours at 37◦C. The residual enzyme
activity is measured after incubation. One Bethesda unit is
deﬁned as the amount of inhibitor that reduces activity by
50% of the control value, and values greater than 0.5U/mL
are signiﬁcant.
5. Thrombocytopenia, Determination of
ADAMTS13:AC,andIts
ClinicalSigniﬁcanceinLC
5.1. Thrombocytopenia. It is well accepted that thrombo-
cytopenia gradually progresses as functional liver capac-
ity decreases [30, 60] (Figure 2(a)). The pathogenesis of
thrombocytopenia in LC includes splenic sequestration in
portal hypertension [61], impaired platelet production due
to decreased synthesis of thrombopoietin in the liver [62]
or due to myelosupression resulting from HCV infection
[63], folic acid deﬁciency, or ethanol chronic consumption
[64], which has a negative eﬀect on megacaryocytopoiesis.
However, our recent studies have provided evidence that in
patients with advanced LC, elevated plasma levels of UL-
VWFM enhance high-shear stress-induced platelet aggrega-
tion, resulting in thrombocytopenia [30].
5.2. ADAMTS13:AC. Our study showed that ADAMTS13:
AC decreased with increasing severity of cirrhosis [30]
(Figure 2(b)). The values determined by act-ELISA cor-
related well with those of the classical VWFM assay and
also closely correlated with ADAMTS13 antigen de-termined
by the antigen-ELISA. These results conﬁrmed that both
ADAMTS13 activity and antigen decreased with increasing
cirrhosis severity [30] (Figures 2(b) and 2(c)), which are
consistent with ﬁndings described by Feys et al. [29]. In
contrast, Lisman et al. showed that both ADAMTS13 activity
and antigen levels were highly variable; however, they did
not distinguish between patients with varying degrees of
cirrhosis [28]. It is unclear why they reached diﬀerent
conclusions from ours. One possible explanation relates to
diﬀerent etiologies: a majority of our patients developed
cirrhosis secondary to HCV infection, whereas in their
study one-half of the patients suﬀered from alcohol abuse-
related cirrhosis. Further, the techniques used to determine
ADAMTS13:AC diﬀered between our study [55–57]a n d
theirs [65]. It is assumed that the collagen binding assay
they used can be highly inﬂuenced by the increased amount
of VWF:Ag in tested cirrhotic plasmas [29], because the
substrate in this assay is intact multimeric VWF. In this
regard, our act-ELISA is performed using VWF73-based
fusion protein, termed GST-VWF73-His, which is readily
cleaved by ADAMTS13 without any protein denaturant, and
thereforetheincreasedamountofVWF:Agintestedplasmas
does not interfere with the assays [57].
As shown in Figure 3, ADAMTS13:ACs were signif-
icantly lower in LC patients with hepatic encephalopathy
(Figure 3(a)), hepatorenal syndrome (Figure 3(b)), and4 International Journal of Hepatology
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Figure 1: Proposed mechanism of platelet thrombi under high shear stress in the absence of ADAMTS13:AC. Unusually large von
Willebrand factor multimers (UL-VWFMs) are produced in vascular endothelial cells (ECs) and stored in Weidel-palade bodies (WPBs).
UL-VWFMs are released from WPBs into the circulation upon stimulation by cytokines, hypoxia, DDAVP, and epinephrine. P-selectin
that comigrates from WPBs anchors UL-VWFMs on the vascular EC surface. Under these circumstances, high shear stress changed the
molecular conformation of UL-VWFMs from a globular to an extended form, allowing ADAMTS13 to access this molecule. In the absence
of ADAMTS13:AC, UL-VWFMs remain uncleaved, allowing them to excessively interact with platelet glycoprotein (GP)Ibα and activate
platelets via intraplatelet signaling, which result in the formation of platelet thrombi. (Partially modiﬁed from Fujimura et al., [49]).
severe esophageal varices than those without [30]. Moreover,
patients with refractory ascites had lower ADAMTS13:AC
levels than patients without ascites or those with easily
mobilized ascites (Figure 3(c)). A multivariate analysis
using all signiﬁcant baseline parameters determined by the
univariate analysis, excluding the Child-Pugh score, showed
spleen volume, blood ammonia, and serum creatinine
independently correlated with ADAMTS13:AC. As a second
step, the three parameters that contribute to the Child-Pugh
classiﬁcation (total bilirubin, albumin, and prothrombin
time) were replaced by the Child-Pugh score. As a result,
the Child-Pugh score and spleen volume were independently
selected, indicating that ADAMTS13:AC is closely related
to the severity of liver disease and splenomegaly in cirrhotic
patients [30].
5.3. VWF:Ag and VWF Multimer Patterns. Plasma levels
of VWF:Ag substantially increase as liver diseases progress
(Figure 2(d))[ 30], as previously reported [41, 42]. This
is presumably attributed to sinusoidal and/or extrahepatic
endothelial damage induced by endotoxin and cytokines
[41, 42, 66, 67]. The VWF:RCo was higher (Figure 2(e))
[30], but the ratio of VWF:RCo/VWF:Ag was lower in
LC patients than that in healthy subjects. These ﬁndings
suggest that increased VWF:Ag appears less functional in
LC patients [30], which are consistent with previous reports
[28]. Nevertheless, our study has clearly shown that the
ratio of VWF:RCo/ADAMTS13:AC progressively increases
with the worsening of chronic liver diseases (Figure 2(f)),
further intensifying an enhanced thrombogenesis with the
progression of liver dysfunction and thrombocytopenia [30].
With regard to VWF multimers, the higher molecular
weight multimer showed greater degradation than in healthy
controls, thus maintaining normal enzyme-to-substrate
(ADAMTS13/UL-VWFMs) ratio to maintain blood ﬂuidity
[29]. We showed that there were three diﬀerent VWFM
patterns in LC patients with lower ADAMTS13:AC (<50 %
ofcontrols):normal-VWFMwasdetectedin53%,degraded-
VWFM in 31%, and UL-VWFM in 16% (Table 1)[ 30]. UL-
VWFM-positivepatientsshowedthelowestADAMTS13:AC
and the highest values of serum creatinine, blood urea
nitrogen, and blood ammonia. In addition, LC patients with
UL- and normal-VWFM had higher levels of VWF:RCoInternational Journal of Hepatology 5
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Figure 2: Platelet counts and plasma levels of ADAMTS13:AC and its related parameters in patients with chronic liver diseases. Platelet
counts decreased with the severity of chronic liver diseases, but no diﬀerence was found between Child B and C (a). Plasma ADAMTS13:AC
determined by ELISA progressively decreased with worsening cirrhosis (b). Arrows indicate patients whose plasma ADAMTS13:AC was
extremely low (<3% of normal control by VWFM assay). The ADAMTS13:AG levels determined by ELISA also decreased with increasing
cirrhosis severity (c), which highly correlated with ADAMTS13:AC measured by the act-ELISA (r = 0.715, P<. 001). The VWF:Ag
increased with the progression of chronic liver diseases, but the diﬀerence between Child B and C did not reach statistical signiﬁcance (d).
The VWF:RCo is higher in liver cirrhosis patients than that in patients with chronic hepatitis and healthy subjects, but it did not diﬀer
among subgroups within liver cirrhosis (e). The VWF:RCo relative to ADAMTS13:AC progressively increased with worsening chronic
liver disease (f). Open circles: normal controls; open triangles: chronic hepatitis; open squares: cirrhosis with Child A; closed triangles:
cirrhosis with Child B; closed circles: cirrhosis with Child C. Shaded area shows normal range. ADAMTS13:AC:ADAMTS13 activity,
ADAMTS13:AG=ADAMTS13 antigen. VWF:Ag=von Willebrand factor antigen, VWF:RCo=von Willebrand factor ristocetin cofactor
activity; ∗P<. 05, ∗∗P<. 01, and ∗∗∗P<. 001 signiﬁcantly diﬀerent between the two groups. (Partially modiﬁed from Uemura et al., [30]).
and Child-Pugh score and lower values of cholinesterase
and hemoglobin than those with degraded-VWFM [30]
(Table 1). The pattern, therefore, appears to shift from
degraded- to normal-VWFM, and ﬁnally to UL-VWFM as
functional liver capacity and renal function deteriorates,
indicating that advanced LC may be a predisposing state
towardplateletmicrothrombiformation,evenintheabsence
of clinically overt thrombotic events [30].6 International Journal of Hepatology
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Figure 3: Relationship of ADAMTS13:AC to the presence or absence of hepatic encephalopathy, hepatorenal syndrome, and ascites in
patients with liver cirrhosis. The ADAMTS13:AC was signiﬁcantly lower in LC patients with hepatic encephalopathy (a) and hepatorenal
syndrome (b) than that those without. Moreover, patients with refractory ascites had lower ADAMTS13:AC than those without ascites
or those with easily mobilized ascites (c). Closed circles indicate patients whose plasma ADAMTS13:AC was extremely low (<3% of
normal control by VWFM assay). ADAMTS13:AC:ADAMTS13 activity; ∗P<. 001 signiﬁcantly diﬀerent between the two groups. (Partially
modiﬁed from Uemura et al., [30]).
Table 1: Comparison of clinical parameters among cirrhotic patients according to VWF multimer patterns.
Variables
VWF multimer pattrens
a versus b a versus c b versus c Degraded
a
(n = 15)
Normal
b
(n = 26)
Unusually large
c
(n = 8)
ADAMTS13:AC (%)
(ELISA) 47 ±24 44 ±13 26 ±14 n.s. P<. 05 P<. 01
VWF:RCo(%) 110±92 196 ±134 216 ±110 P<. 05 P<. 05 n.s.
Child-Pugh score 8.6 ±2.51 0 .9 ±2.11 2 .4 ±1.7 P<. 01 P<. 005 n.s.
Serum albumin (g/dL) 3.07 ±0.54 2.85 ±0.54 2.59 ±0.25 n.s. P<. 05 n.s.
Cholinesterase (IU/L) 126 ±62 78 ±64 60 ±36 P<. 05 P<. 02 n.s.
Total cholesterol
(mg/dL) 142 ±51 93 ±45 88 ±40 P<. 01 P<. 03 n.s.
Hemoglobin (g/dL) 11.0 ±1.79 .3 ±2.08 .9 ±1.7 P<. 02 P<. 02 n.s.
Serum creatinine
(mg/dL) 1.06 ±0.72 1.11 ±0.79 2.43 ±2.16 n.s. P<. 05 P<. 03
Blood urea nitrogen
(mg/dL) 22 ±17 30 ±21 74 ±62 n.s. P<. 01 P<. 01
Blood ammonia (μg/dL) 87 ±50 100 ±39 144 ±53 n.s. P<. 05 P<. 05
VWF: von Willebrand factor; ADAMTS13:AC:ADAMTS13 activity; ELISA: enzyme-linked immunosorbent assay; VWF:RCo: VWF ristocetin cofactor
activity; n.s.: not signiﬁcant. (Partially modiﬁed from Uemura et al., [30]).
6.Mechanismof Decreased
ADAMTS13:ACinLC Patients
The mechanism responsible for the decrease in ADAMTS13:
AC in advanced LC may include enhanced consumption due
to the degradation of large quantities of VWF:AG [20],
inﬂammatory cytokines [68, 69], and/or ADAMTS13 plasma
inhibitor[9,10].ItiscontroversialwhetherADAMTS13deﬁ-
ciency is caused by decreased production in the liver; Kume
et al. reported that HSC apoptosis plays an essential role
in decreased ADAMTS13:AC using dimethylnitrosamine-
treated rats, but not carbon tetrachloride- (CCl4-) treatedInternational Journal of Hepatology 7
animals [70], whereas Niiya et al. found upregulation of
ADAMTS13 antigen and proteolytic activity in liver tissue
using rats with CCl4-induced liver ﬁbrosis [71]. We observed
theinhibitorofADAMTS13in83%ofpatientswithsevereto
moderate ADAMTS13 deﬁciency, but its inhibitory activity
was in a marginal zone between 0.5 and 1.0BU/mL in most
cases except in cases of a TTP patient (2.0BU/mL) and a
patientwithsevereADAMTS13deﬁciency(3.0BU/mL)[30].
Interestingly, IgG-type autoantibodies speciﬁc to puriﬁed
plasma derived-ADAMTS13 were detected by Western blot-
ting only in ﬁve end-stage cirrhotics with severe ADAMTS13
deﬁciency (<3%) corresponding to TTP [30]. One patient
showed an apparent TTP [35], while the other four cir-
rhotics did not show apparent clinical features of TTP but
had complications of hepatorenal syndrome, spontaneous
bacterial peritonitis (SBP), marked inﬂammation together
with cytokinemia, and advanced hepatocellular carcinoma
(HCC) [30]. Various clinical conditions, including infection,
malignancies, and certain drugs, can lead to acquired TTP
[72]. In advanced LC patients, endotoxemia is frequently
detected [42, 73], and SBP sometimes occurs [74]. HCC
is highly complicated as the cirrhotic stage progresses
[75], suggesting a high-risk state of platelet microthrombi
formation. Some end-stage LC patients with extremely low
ADAMTS13:AC and its IgG inhibitor may reﬂect conditions
similar to TTP or may reﬂect “subclinical TTP” [21]. Further
studies will be necessary to clarify whether inhibitors other
than the IgG inhibitor might be involved in cirrhotics with
lower ADAMTS13:AC.
Alternatively, cytokinemia [25, 68, 69, 76]a n de n d o -
toxemia [25, 77] are additional potential candidates for
decreasing plasma ADAMTS13:AC. Recent investigations
demonstrated that IL-6 inhibited the action of ADAMTS13
under ﬂow conditions and both IL-8 and TNF-α stimu-
lated the release of UL-VWFM in human umbilical vein
endothelial cells in vitro [68]. It remains to be clariﬁed
whether IL-6 directly hampers the cleavage of UL-VWFM
or downregulates gene expression of ADAMTS13 with
modiﬁcation of promoter activity. IFN-γ,I L - 4 ,a n dT N F - α
also inhibit ADAMTS13 synthesis and activity in rat primary
HSC [69]. In addition, ADAMTS13 deﬁciency associated
with inﬂammation promoted formation of UL-VWFM [78],
and intravenous infusion of endotoxin to healthy volunteers
caused a decrease in plasma ADAMTS13:AC together with
theappearanceofUL-VWFM[77].Inpatientswithalcoholic
hepatitis, especially in severe cases complicated by LC,
ADAMTS13:AC concomitantly decreased, and VWF:Ag
progressively increased with increasing concentrations of
these cytokines from normal range to over 100pg/mL
[25]. Plasma endotoxin concentration inversely correlated
with ADAMTS13 activity and was higher in patients with
UL-VWFM than that those without [25]. From these
results as well as our own, marked cytokinemia and/or
enhanced endotoxemia may be closely related to decreased
ADAMTS13:AC and the appearance of UL-VWFM [25].
It will be necessary to clarify what types of inhibitor may
be involved in association with inﬂammatory cytokines and
endotoxin.
7. TypicalTTP inPatientswith
LiverDiseases
We previously encountered a patient with HCV-related LC
who was compromised by fatal TTP [35]. This case showed
advanced LC and rigid ascites. As reported in the literature,
since 1979, there have been 13 patients with liver diseases
who developed TTP [35, 79–90]. Five of them were treated
with IFN therapy, but the remaining 8 were not. Three
of them showed evidence of autoimmune hepatitis, one of
which was complicated by systemic lupus erythematosus
(SLE). The remaining 4 patients had HCV-related LC,
hepatitis B virus- (HBV-) related LC, alcoholic LC, or hae-
mochromatosis. IFN may be able to induce autoimmune
reactions, resulting in the generation of autoantibodies
against ADAMTS13, although this phenomenon has yet to
beconﬁrmed.Ontheotherhand,irrespectiveofIFNtherapy,
HCV infection and/or advanced LC itself may contribute to
the development of TTP.
There is general consensus that the overall prevalence
of serum non-organ-speciﬁc autoantibodies is signiﬁcantly
higher in patients with HCV (about one third of all cases)
than that in both healthy subjects and patients with HBV
[91–93], but not alcoholic liver injury. In addition, HCV
infection was conﬁrmed in ﬁve of 10 patients (50%) who
developed thrombotic microangiopathy (TMA) after living-
donor liver transplantation [94]. In our study, the etiology of
our ﬁve end-stage LC patients with IgG-type autoantibodies
was HCV in 2, HBV in 1, PBC in 1, and cryptogenic in 1, but
none of the patients displayed alcohol-abuse-related cirrho-
sis[30].Nevertheless,thediagnosisofTTPmaybehampered
by clinical features accompanying hepatic failure similar to
the pentad of typical TTP (fever, thrombocytopenia, renal
failure, ﬂuctuating neurological signs, and microangiopathic
hemolytic anemia) [11, 12].
8. Possible Therapeutic Approaches of
ADAMTS13 Supplementation for
Patients withDecompensated LC
Fresh frozen plasma (FFP) infusion is commonly used to
correct the prolonged prothrombin time in patients with
advancedchronicliverdisease,butexactindicationforitsuse
has not been clearly deﬁned [95]. The aim of FFP infusions
is usually either to improve the coagulopathy before invasive
procedures or to control ongoing bleeding from various sites
in patients with vitamin K-unresponsiveness prolonged pro-
thrombin time. The mean prothrombin time was improved
by the infusion of 2–6 units of FFP, but only 12.5% of the
retrospective study group and 10% of the prospective study
groups showed reversal of their coagulopathy, and higher
volume (6 or more units) may be more eﬀective but rarely
is employed [96]. However, attention should be directed
to complications including the risk of infection, allergic
reaction,andacutevolumeexpansionleadingtoheartfailure
or pulmonary edema [95, 96].
With regard to FFP infusion as a unique source of
ADAMTS13, we clearly showed that preexisting UL-VWFMs8 International Journal of Hepatology
in the plasma of USS patients began to diminish within 1
hour and completely diminished 24 hours after ADAMTS13
was replenished with infusions of FFP [97]. Retrospectively,
these results indicated that exogenous ADAMTS13 could
eﬃciently cleave both UL-VWFMs that preexisted in the
circulation and the newly produced molecules at the ECs
surface. Advanced LC is known to be a predisposing state
towardplateletmicrothrombiformation,evenintheabsence
of clinically overt thrombi [30]. In our study, UL-VWFM-
positive patients showed the lowest ADAMTS13:AC and the
highest values of serum creatinine, blood urea nitrogen, and
blood ammonia, and the VWFM patterns appeared to shift
from degraded to normal VWFM and ﬁnally to UL-VWFM
as functional liver capacity and renal function deteriorated
(Table 1). From these results, it may be reasonable to
assume that advanced LC patients with severe to moderate
deﬁciency of ADAMTS13:AC (<3% to ∼25% of normal
control) could be candidates for FFP infusion as a source of
ADAMTS13. It is necessary to evaluate the eﬀectiveness of
FFP administration to patients with ADAMTS13:AC levels
from 25% to 50%.
Alternatively, our recent study demonstrated that plasma
ADAMTS13:AC is reduced in VOD patients after stem cell
transplantation (SCT) (12–32% of normal) compared to
non-VOD patients (57–78% of normal), even before any
conditioning regimen and throughout SCT, and that the
activity might thus be a predictor for the development of
hepatic VOD [22]. A multicenter, prospective, randomized
controlledstudyrevealedthatprophylacticFFPinfusionmay
be instrumental in preventing the development of hepatic
VOD after SCT [23] .T h ei m b a l a n c ec a u s e db yd e c r e a s e d
ADAMTS13:AC versus increased production of VWF:Ag
before and during the early stage after SCT would contribute
to a microcirculatory disturbance that could ultimately
lead to VOD [23]. The supplementation of ADAMTS13
by prophylactic FFP infusion may suppress the increase in
VWF:AG that is extensively released from damaged SEC.
Furthermore, we ﬁrst reported in 2006 that a signiﬁcant
reduction of ADAMTS13:AC with a concomitant appear-
ance of UL-VWFM was consistently observed in patient
plasma soon after liver transplantation [31]. These changes
were closely related to liver-graft dysfunction, ischemia-
reperfusioninjury,andacuterejection.TheADAMTS13:AC
often decreased to less than 10% of normal controls, concur-
rent with severe thrombocytopenia. The organ dysfunction
appeared to be restricted to the liver graft, indicating that
a decrease of plasma ADAMTS13:AC coupled with the
appearance of UL-VWFM was attributed to a mechanism of
“local TTP” within the liver graft [21, 31]. It is, therefore,
extremely important to monitor plasma ADAMTS13:AC in
the treatment of thrombocytopenia associated with allograft
dysfunction after liver transplantation. This is because the
infusions of platelet concentrate under conditions of an
imbalance of decreased ADAMTS13:AC to enhanced UL-
VWFM production might further exacerbate the formation
of platelet aggregates mediated by uncleaved UL-VWFM,
leading to graft failure via the “local TTP” mechanism
[21, 31]. FFP infusion as ADAMTS13 replacement therapy
may improve both liver dysfunction and thrombocytopenia
in liver transplant patients. From this point of view, we
are particularly interested in conducting clinical trials with
recombinant ADAMTS13 preparations not only in patients
with advanced LC but also in patients with VOD and liver
transplantations.
9. Conclusion andFuturePerspectives
The introduction of ADAMTS13 to the ﬁeld of hepatology
not only enabled us to conﬁrm the diagnosis of TTP early
but also provided novel insight into the pathophysiology of
liver diseases. Some diseases were shown to be TTP itself, but
others did not show any apparent clinical features of TTP,
even in the presence of extremely decreased ADAMTS13:AC
and increased UL-VWFM corresponding to TTP. Such TTP-
like states, but without disseminated intravascular coagula-
tion, might be “subclinical TTP” as seen in advanced liver
cirrhotics [30] and SAH patients [24–27] or “local TTP”
as shown in patients with hepatic VOD after SCT [22, 23]
and patients with adverse events after living-donor liver
transplantation [31, 32]. Essentially, one would be unable to
detect such TTP-like phenomena without the determination
of ADAMTS13:AC, because the interaction of ADAMTS13
and UL-VWFM is the initial step in hemostasis, and their
abnormalities do occur in the absence of apparent imbalance
in other hemostatic factors and/or irrespective of the pres-
ence or absence of abnormal conventional hemostatic fac-
tors. The origin of VWF, the substrate of ADAMS13, indeed
may be transformed hepatic sinusoidal and/or extrahepatic
endothelial cells, but not hepatocytes. The procoagulant and
anticoagulant proteins synthesized in hepatocytes decrease
as liver disease progresses, whereas VWF markedly increases.
Under such circumstances, ADAMTS13 deﬁciency may lead
to a microcirculatory disturbance not only in the liver,
but also in the systemic circulation. The determination of
ADAMTS13 and its related parameters thus will be quite
useful for improved understanding of the pathophysiol-
ogy and for providing appropriate treatments especially
in severe liver disease patients. It will be necessary to
measure ADAMTS13:AC when patients with unexplained
thrombocytopenia are encountered in the course of liver
disease. When “subclinical or local TTP” status would be
conﬁrmed,FFPinfusionasADAMTS13replacementtherapy
may improve both liver dysfunction and thrombocytopenia.
Further investigation will be necessary to deﬁne candidates
for ADAMTS13 supplementation therapy and to evaluate its
potential therapeutic eﬃcacy in advanced LC patients.
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